Display options
Cite
Jambrovics K, Uray IP, Keillor JW, et al. Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers (Basel). 2020;12(3)doi: 10.3390/cancers12030648.
Jambrovics, K., Uray, I. P., Keillor, J. W., Fésüs, L., & Balajthy, Z. (2020). Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers, 12(3), . https://doi.org/10.3390/cancers12030648
Jambrovics, Károly, et al. "Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2." Cancers vol. 12,3 (2020). doi: https://doi.org/10.3390/cancers12030648
Jambrovics K, Uray IP, Keillor JW, Fésüs L, Balajthy Z. Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers (Basel). 2020 Mar 11;12(3). doi: 10.3390/cancers12030648. PMID: 32168763; PMCID: PMC7139906.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Mar 11;12(3). doi: 10.3390/cancers12030648.

Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2.

Cancers

Károly Jambrovics, Iván P Uray, Jeffrey W Keillor, László Fésüs, Zoltán Balajthy

Affiliations

  1. Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  2. Department of Clinical Oncology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  3. Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
  4. MTA DE Apoptosis, Genomics and Stem Cell Research Group of the Hungarian Academy of Sciences, 4032 Debrecen, Hungary.

PMID: 32168763 PMCID: PMC7139906 DOI: 10.3390/cancers12030648

Abstract

Randomized trials in acute promyelocytic leukemia patients have shown that treatment with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior in efficacy to monotherapy, with significantly decreased mortality. So far, there are little data available to explain the success of the ATRA and ATO combination treatment in molecular terms. We showed that ATRA- and ATO-treated cells had the same capacity for superoxide production, which was reduced by two-thirds in the combined treatment. Secreted inflammatory biomarkers (monocyte chemoattractant protein-1 [MCP-1], interleukin-1 beta [IL-1β] and tumor necrosis factor-α [TNF-α]) were significantly decreased and were further reduced in a transglutaminase 2 (TG2) expression-dependent manner. The amount of secreted TNF-α in the supernatant of NB4 TG2 knockout cells was close to 50 times lower than in ATRA-treated differentiated wild-type NB4 cells. The irreversible inhibitor of TG2 NC9 not only decreased reactive oxygen species production 28-fold, but decreased the concentration of MCP-1, IL-1β and TNF-α 8-, 15- and 61-fold, respectively in the combined ATRA + ATO-treated wild-type NB4 cell culture. We propose that atypical expression of TG2 leads to the generation of inflammation, which thereby serves as a potential target for the prevention of differentiation syndrome.

Keywords: NB4; acute promyelocytic leukemia; all-trans retinoic acid (ATRA); arsenic trioxide (ATO), ATRA and ATO combination treatment

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

  1. EMBO J. 1996 Sep 16;15(18):4949-58 - PubMed
  2. Blood. 2010 Nov 11;116(19):3933-43 - PubMed
  3. Blood. 2009 Dec 24;114(27):5512-21 - PubMed
  4. Oxid Med Cell Longev. 2018 Feb 11;2018:5730395 - PubMed
  5. Cell Death Dis. 2016 Jun 02;7(6):e2244 - PubMed
  6. Blood. 2009 Jan 22;113(4):775-83 - PubMed
  7. Mol Carcinog. 2015 Oct;54(10):947-58 - PubMed
  8. Blood. 2011 Jun 16;117(24):6425-37 - PubMed
  9. Int Rev Cell Mol Biol. 2012;294:1-97 - PubMed
  10. Science. 2010 Apr 9;328(5975):240-3 - PubMed
  11. J Med Chem. 2017 Sep 28;60(18):7910-7927 - PubMed
  12. Exp Physiol. 2019 Apr;104(4):447-452 - PubMed
  13. Best Pract Res Clin Haematol. 2003 Sep;16(3):453-61 - PubMed
  14. Sci Rep. 2019 Jul 1;9(1):9414 - PubMed
  15. J Cancer Res Clin Oncol. 2010 Apr;136(4):493-502 - PubMed
  16. Blood. 1999 Nov 15;94(10):3315-24 - PubMed
  17. Blood. 2017 Mar 9;129(10):1275-1283 - PubMed
  18. Blood. 2006 Sep 15;108(6):2045-54 - PubMed
  19. Haematologica. 2019 Mar;104(3):505-515 - PubMed
  20. Blood. 1994 Nov 1;84(9):3001-9 - PubMed
  21. Amino Acids. 2013 Jan;44(1):63-72 - PubMed
  22. Toxicol Appl Pharmacol. 2010 May 1;244(3):385-92 - PubMed
  23. Trends Biochem Sci. 2002 Oct;27(10):534-9 - PubMed
  24. Blood. 2008 Mar 1;111(5):2505-15 - PubMed
  25. Biochem Pharmacol. 2010 Dec 15;80(12):1921-9 - PubMed
  26. Physiol Rev. 2014 Apr;94(2):383-417 - PubMed
  27. Am J Transl Res. 2011 Feb;3(2):166-79 - PubMed
  28. Blood. 2006 May 1;107(9):3469-73 - PubMed
  29. Oncotarget. 2018 Oct 2;9(77):34495-34505 - PubMed
  30. Oncogene. 2017 May 25;36(21):2981-2990 - PubMed

Publication Types

Grant support